亨迪药业：预计2025年归母净利润同比下降66.14%-57.40%

Core Viewpoint - Hendi Pharmaceutical expects a significant decline in net profit for 2025, projecting a range of 31 million to 39 million yuan, which represents a year-on-year decrease of 66.14% to 57.40% [1] Group 1 - The primary reason for the profit decline is intensified market competition for its main product, ibuprofen raw materials, and certain specialty raw material products, leading to a decrease in gross margin [1] - Additionally, the company's cash management interest income has decreased due to falling interest rates [1]